Wall Street Has a Positive Outlook on uniQure N.V. (QURE) Despite Challenges From The FDA

​uniQure N.V. (NASDAQ:QURE) is one of the Hottest Small Cap Stocks to Buy Now. Wall Street has a positive outlook on uniQure N.V. (NASDAQ:QURE) despite the regulatory challenges from the FDA for its experimental gene therapy called AMT-130. On November 12, Yanan Zhu from Wells Fargo also reiterated a Buy rating on uniQure N.V. (NASDAQ:QURE), but lowered the price target from $80 to $60. A day earlier, TD Cowen analyst Joseph Thome had maintained a Buy rating on the stock without disclosing any price target ...